Search the Newsreel

Edgewise Therapeutics Inc (EWTX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Edgewise Therapeutics Inc (EWTX), listing major shareholders and their proportions, as well as a breakdown of shareholder types. It also provides institutional shareholding data over various quarters and lists related ETFs holding EWTX shares.

Edgewise Therapeutics Inc (EWTX) Balance Sheet

This article provides a detailed balance sheet for Edgewise Therapeutics Inc (EWTX), presenting quarterly financial data for assets, liabilities, and shareholders' equity. It covers various line items including cash, investments, fixed assets, accrued expenses, and retained earnings, allowing for an in-depth analysis of the …

Edgewise Therapeutics Inc (EWTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Edgewise Therapeutics Inc (EWTX), detailing its performance based on various indicators and moving averages. It offers insights into the stock's current technical ratings, including buy, sell, and neutral signals from MACD, RSI, KDJ, and other common technical …

First Light Asset Management LLC Has $31.56 Million Stake in Edgewise Therapeutics, Inc. $EWTX

Edgewise Therapeutics, Inc. Revenue Breakdown – NASDAQ:EWTX

This page on TradingView.com provides financial information for Edgewise Therapeutics, Inc. (EWTX) on the Nasdaq Stock Market. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segments. The article indicates that the market is closed, with no trades currently …

Edgewise Therapeutics Inc (EWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Edgewise Therapeutics Inc (EWTX), focusing on its volatility, financial risk, and investment risk. It presents various financial metrics such as Beta, VaR, Maximum Drawdown, Volatility, Return-to-Drawdown Ratio, Skewness, Realised Volatility, and Liquidity. The data covers different timeframes, …

Edgewise Therapeutics, Inc. $EWTX Shares Sold by Granahan Investment Management LLC

EWTX|Edgewise Therapeutics Inc|Price:40.840|Chg%:+1.550

Edgewise Therapeutics Inc. (EWTX) stock closed at $40.84, up 3.94%, with a market cap of $4.39 billion. Analysts have a "Buy" rating for EWTX, with a target price of $49.667, indicating a 26.41% upside. The company is focused on developing novel therapeutics for muscular …

Edgewise Therapeutics (EWTX) Trades At A Rich P B, Is The Premium Justified?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. How Edgewise Therapeutics Stock Has Been Trading Recently Edgewise Therapeutics (EWTX) has drawn investor attention after a period of mixed short term trading, with …

Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $55

Evercore has reiterated its Buy rating on Edgewise Therapeutics (EWTX.US) and increased its price target to $55. This revision suggests continued confidence from the analyst firm in the company's prospects.

Form 4 Edgewise Therapeutics Inc For: 17 July By Investing.com

This article reports on a Form 4 filing by Edgewise Therapeutics Inc. for July 17th. It briefly mentions the company's stock symbol (EWTX) and its percentage change for the day. The core content is a very short news piece about the Form 4 filing, …

Edgewise Therapeutics director gets 16,377 options | EWTX Insider Trading

Edgewise Therapeutics director Jonathan D. Root was granted 16,377 stock options on June 5, 2026, with an exercise price of $35.59 per share and an expiration date of June 5, 2036. The options will fully vest on the earlier of June 5, 2027, or …

Edgewise Therapeutics (NASDAQ: EWTX) books big gain on $1.55B sevasemten sale

Edgewise Therapeutics has completed the sale of its sevasemten muscular dystrophy program to Servier Pharmaceuticals for an upfront cash payment of $1.55 billion, with potential for an additional $1.1 billion in milestone payments, totaling up to $2.65 billion. This transaction significantly strengthens Edgewise's balance …

Edgewise Therapeutics Stock Rides A 5-Day Winning Streak To A 23% Gain

Why Edgewise Therapeutics (EWTX) Is Up 13.3% After Phase 2 EDG-7500 HCM Data Release

EWTX Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift Shares - Full Year Guidance

Edgewise Therapeutics (EWTX) Stock Looks Fully Priced After Phase 2 HCM Progress

EWTX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock Reaction - Management Tone Analysis

Assessing Edgewise Therapeutics (EWTX) Valuation After A Sharp Recent Share Price Move

Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal

Do Edgewise Therapeutics' (EWTX) New Stock Grants Clarify or Complicate Its Pipeline Execution Story?

EDGEWISE THERAPEUTICS Earnings Results: $EWTX Reports Quarterly Earnings

Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights